In France, 1022 cases of pediatric multisystem inflammatory syndrome (PIMS) were reported between March 2020 and the end of February 2022. Seized by the Director General of Health, the HAS considers that it is now possible to lift the contraindication to the primary vaccination against the Covid-19 in children and adolescents who presented PIMS post-SARS-CoV-2 infection. The HAS, however, specifies that before vaccinating, it is necessary to respect a period of at least 3 months, after the cure of PIMS.
To support its opinion, the HAS relies on several elements, including:
- the lack of evidence of a possible link between Covid-19 vaccines and very rare cases of multisystem inflammatory syndrome in the PRAC analysis (Pharmacovigilance Risk Assessment Committee) ;
- the effectiveness of vaccination in significantly reducing PIMS cases;
- the lack of available data on the risk of a second PIMS, in children or adolescents with a history of post-Covid-19 PIMS, regardless of their vaccination status;
- the favorable position to vaccination of children with a history of PIMS of the group of experts COPIL PIMS Franceas well as the recommendations of several countries to vaccinate children or adolescents with a history of PIMS.
In the course of its opinion, the HAS highlights that its vaccination technical commission will soon carry out work to formulate recommendations on the vaccine strategy against SARS-CoV-2 in the medium and long term. This reflection will take into account recent data, in real life, on vaccine efficacy in children in the context of Omicron, those related to the risk of severe forms in this population. Available data on new vaccines and current vaccines that have been adapted to the different circulating variants will also be integrated.
 COPIL PIMS report of 01/23/2022 that HAS was able to read.
Florencia Gaudin – Head of Department
Marina Malikité – Press officer – 01 55 93 73 52
Stéphanie Lecomte – Press Officer – 01 55 93 73 17
Mohamed Bouhadda – Press officer – 01 55 93 73 18
Quentin Nogués – Press officer – 01 55 93 38 03
These numbers are reserved for journalists, we are not authorized to respond to other requests.
- Contact Us
eNrNWF1v2jAUfedXRHlPQoBCmALVxtoNqdUYLdq0F2ScSzELceqPQPfr5xC60clRV1NLfcQ2515fn3t84vh8t0mdAhgnNBu4od90HcgwTUh2N3Bnt5de5J4PG / EaFeh4WeQ352EUug5OEecDt5z3F4Ay7n + / vvoICgGYO2w4MV2sAYsn66Qgqf8Z8dU1yss1TlxQkjgbECuaDNxciv2oE3PBVB7DLWU / eY4wxMFh5Hh2Pe8cj8dBCfYfqJIDu0LZnRZ0yYwwsWQMMjFCAu4oe9BD43nY6vR73aZRCMKnwKlkGCZIrCaMFiSBRB8JpRyMgiy3yQ2wIgVRBtGCB2u84UbgaI12U7gf65N + r2ZHYie8phd2O1HYbrWibu / M7IzZUan05FGbCPJ5u93q9M76wZIFuCyoF / a9FAoALwEvRR6mmWDgkSwhGAnVAx4qh3NGNrRAGJPsMJqriJ7MvJwYFofwCWUCpZYOlvDRU4paisPg / lkCJYTnKXrw1zw3LRViSE0DU0JibyPlDm6ZkrZU1ewf / EymafDCrGcH4bGUcalrIyoVYfX6czk1LcRIdQHs6k / UTDLF7sBFAvz1YH / RTH9dTOQiJdhUFZVuSeBiNh3Xi + Ib05MPiMOM2ROUb2oXdMtfX6iOiWEp + 3yvtVrQnCXhvNWPumHUNu7DH4qFNffchWQ0h0BJGOGnKNM4W9JTNUkRWw / 1SOu3xOi9b6MYpVDj3OaGCqeo / Gg0rTWLvUasJrSgny5uTRn2VQJ7uNn / 1EKTZPCHG2byb aoF3 + + + NOUXyuTfzl3VGJxHOevhX1OlHbrAiS6TVoJUTO3wXBdrv1V4h7HKli A1c2QO7H2UWHEglSOrpNpS6ovqDn7ZIZv27HMe5VTfffj / wd9rYwgm4YSzqOTdmgiPL15f1 / + abmtpT57okL0we4O8FwZbrksu9JbrpJtEnWt2yZRAfF kuSc1bUS0v46B6pxo24qB8oxo2fgP4oUvA